Novispirin G10-Induced Lung Toxicity in a Klebsiella pneumoniae Infection Model

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 12, 2003, Pages 3901-3906

  Bartlett, Karen H ^a,c   McCray Jr , Paul B ^b   Thorne, Peter S ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CATHELICIDIN; CYTOKINE; G 10; HEMOGLOBIN; INTERLEUKIN 6; NOVISPIRIN; PROTEIN; SODIUM CHLORIDE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; BLOOD ANALYSIS; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; ENTEROBACTER INFECTION; EX VIVO STUDY; KLEBSIELLA PNEUMONIAE; LUNG LAVAGE; LUNG TOXICITY; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BRONCHOALVEOLAR LAVAGE FLUID; ENDOTOXINS; HEMOGLOBINS; INTERLEUKIN-6; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; TOBRAMYCIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0344012011     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.12.3901-3906.2003     Document Type: Article

References (29)

1. Brogden, K. A., V. C. Kalfa, M. R. Ackermann, D. E. Palmquist, P. B. McCray, Jr., and B. F. Tack. 2001. The ovine cathelicidin SMAP29 kills ovine respiratory pathogens in vitro and in an ovine model of pulmonary infection. Antimicrob. Agents Chemother. 45:331-334.
2. De Haas, C. J. C., P.-J. Haas, K. P. M. van Kessel, and J. A. G. van Strijp. 1998. Affinities of different proteins and peptides for lipopolysaccharide as determined by biosensor technology. Biochem. Biophys. Res. Commun. 252: 492-496.
3. Fidai, S., S. W. Farmer, and R. E. Hancock. 1997. Interaction of cationic peptides with bacterial membranes. Methods Mol. Biol. 78:187-204.
4. Fisher, L. D., and G. van Belle. 1993. Biostatistics: a methodology for the health sciences, p. 600-622. John Wiley & Sons, New York, NY.
5. 106-138-IgG, that binds and neutralizes endotoxin and kills gram-negative bacteria. J. Infect. Dis. 175:621-632.
6. Ganz, T. 2002. Antimicrobial polypeptides in host defense of the respiratory tract. J. Clin. Investig. 109:693-697.
7. Gennaro, R., M. Zanetti, M. Benincasa, R. Podda, and M. Miani. 2002. Pro-rich antimicrobial peptides from animals: structure, biological functions and mechanism of action. Curr. Pharm. Des. 8:763-778.
8. Greenberger, M. J., S. L. Kunkel, R. M. Strieter, N. W. Lukacs, J. Bramson, J. Gauldie, F. L. Graham, M. Hitt, J. M. Danforth, and T. J. Standiford. 1996. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J. Immunol. 157:3006-3012.
9. ++ down-regulate E-cadherin and upregulate alpha 2 beta 1 integrin function, activating keratinocyte migration on type I collagen. J. Investig. Dermatol. 104:768-774.
10. Hancock, R. E. W. 1997. Peptide antibiotics. Lancet 349:418-422.
11. Hirata, M., Y. Simomura, M. Yoshida, S. C. Wright, and J. W. Larrick. 1994. Endotoxin-binding synthetic peptides with endotoxin-neutralizing, antibacterial and anticoagulant activities. Prog. Clin. Biol. Res. 388:147-159.
12. Larrick, J. W., M. Hirata, H. Zheng, J. Zhong, D. Bolin, J.-M. Cavaillon, H. S. Warren, and S. C. Wright. 1994. A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J. Immunol. 152:231-240.
13. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved Standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. Saiman, L., S. Tabibi, T. D. Starner, P. San Gabriel, P. L. Winokur, H. P. Jia, P. B. McCray, Jr., and B. F. Tack. 2001. Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis. Antimicrob. Agents Chemother. 45:2838-2844.
15. Sawa, T., K. Kurahashi, M. Ohara, M. A. Gropper, V. Doshi, J. W. Larrick, and J. P. Wiener-Kronish. 1998. Evaluation of antimicrobial and lipopolysaccharide-neutralizing effects of a synthetic CAP18 fragment against Pseudomonas aeruginosa in a mouse model. Antimicrob. Agents Chemother. 42:3269-3275.
16. Sawai, M. V., A. J. Waring, W. R. Kearney, P. B. McCray, Jr., W. R. Forsyth, R. I. Lehrer, and B. F. Tack. 2002. Impact of single-residue mutations on the structure and function of ovispirin/novispirin antimicrobial peptides. Protein Eng. 15:225-232.
17. Schwab, U., P. Gilligan, J. Jaynes, and D. Henke. 1999. In vitro activities of designed antimicrobial peptides against multidrug-resistant cystic fibrosis pathogens. Antimicrob. Agents Chemother. 43:1435-1440.
18. Scott, M. G., A. C. E. Vreugdenhil, W. A. Buurman, R. E. W. Hancock, and M. R. Gold. 2000. Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J. Immunol. 164:549-553.
19. Skerlavaj, B., M. Benincasa, A. Risso, M. Zanetti, and R. Gennaro. 1999. SMAP-29: a potent antibacterial and antifungal peptide from sheep leukocytes. FEBS Lett. 463:58-62.
20. Steinberg, D. A., and R. I. Lehrer. 1997. Designer assays for antimicrobial peptides. Methods Mol. Biol. 78:169-186.
21. Steinstraesser, L., B. F. Tack, A. J. Waring, T. Hong, L. M. Boo, M.-H. Fan, D. I. Remick, G. L. Su, R. I. Lehrer, and S. C. Wang. 2002. Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns. Antimicrob. Agents Chemother. 46:1837-1843.
22. Steinstraesser, L., O. Burghard, J. Nemzek, M. H. Fan, A. Merry, D. I. Remick, G. L. Su, H. U. Steinau, and S. C. Wang. 2003. Protegrin-1 increases bacterial clearance in sepsis but decreases survival. Crit. Care Med. 31:221-226.
23. Tack, B. F., M. V. Sawai, W. R. Kearney, A. D. Robertson, M. A. Sherman, W. Wang, T. Hong, L. M. Boo, H. Wu, A. J. Waring, and R. I. Lehrer. 2002. SMAP-29 has two LPS-binding sites and a central hinge. Eur. J. Biochem. 269:1181-1189.
24. Thorne, P. S. 2000. Inhalation toxicology models of endotoxin- and bioaerosol-induced inflammation. Toxicology 152:13-23.
25. Thorne, P. S., P. B. McCray, Jr., T. S. Howe, and M. A. O'Neill. 1998. Early-onset inflammatory responses in vivo to adenoviral vectors in the presence or absence of LPS-induced inflammation. Am. J. Respir. Cell Mol. Biol. 20:1155-1164.
26. Tietz, N. W. (ed.). 1987. Fundamentals of clinical chemistry. WB Saunders Co., Philadelphia, Pa.
27. Travis, S. M., N. N. Anderson, W. R. Forsyth, C. Espiritu, B. D. Conway, E. P. Greenberg, P. B. McCray, Jr., R. I. Lehrer, M. J. Welsh, and B. F. Tack. 2000. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect. Immun. 68:2748-2755.
28. Travis, S. M., B. A. Conway, J. Zabner, J. J. Smith, N. N. Anderson, P. K. Singh, E. P. Greenberg, and M. J. Welsh. 1999. Activity of abundant antimicrobials of the human airway. Am. J. Respir. Cell Mol. Biol. 20:872-879.
29. Zanetti, M., R. Gennaro, and D. Romeo. 1995. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 374:1-5.